AS2863619 NEW
| Price | $133 | $189 | $289 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-11-09 |
Product Details
| Product Name: AS2863619 | CAS No.: 2241300-51-4 |
| Purity: 100.00% | Supply Ability: 10g |
| Release date: 2025/11/09 |
Product Introduction
Bioactivity
| Name | AS2863619 |
| Description | AS2863619 is an oral inhibitor of cyclin-dependent kinase 8 (CDK8) and CDK19. Inhibition of CDK8/19 can enhance the activation of STAT5, thereby activating the Foxp3 gene. It can convert antigen-specific effector/memory T cells into Foxp3+ regulatory T cells to study various immune diseases. |
| In vitro | METHODS: Mouse CD4 T cells were treated with AS2863619 (1 μM; 22 hours), and the possible effects of AS2863619 on STAT5 phosphorylation during Foxp3 induction in Tconv cells were investigated. RESULTS AS2863619 inhibited the PSP motif serine phosphorylation of STAT5b to about 40%, while increasing the tyrosine phosphorylation of the C-terminal domain to about 160%; the inhibitory effect of AS2863619 on STAT5b serine phosphorylation was dose-dependent with Foxp3 induction. [1] |
| In vivo | METHODS: Mice were orally treated with AS2863619 (3, 10, or 30 mg/kg). Plasma samples were collected from mice at 1, 2, 4, 8, and 24 hours after administration, and drug levels were determined by high-performance liquid chromatography-tandem mass spectrometry. RESULTS Compared with control mice, AS2863619 treatment after 2,4-dinitrofluorobenzene (DNFB) sensitization suppressed the extent of secondary responses, with less inflammatory cell infiltration into the skin and a lower proportion of interferon-γ (IFN-γ) cells in regional lymph nodes; depletion of Tregs abolished AS2863619-induced suppression before the induction of secondary responses. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 245 mg/mL (604.58 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (12.34 mM), Sonication is recommended. |
| Keywords | STAT5 | STAT | Inhibitor | inhibit | Cyclin dependent kinase | CDK8 | CDK19 | CDK | AS-2863619 | AS2863619 | AS 2863619 |
| Inhibitors Related | Ribociclib | Nifuroxazide | Balsalazide disodium dihydrate | Abemaciclib | Fludarabine | Niclosamide | CASIN | Diosgenin | Niclosamide olamine | Artesunate | Dinaciclib | Abemaciclib methanesulfonate |
| Related Compound Libraries | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Cancer Metabolism Compound Library | JAK-STAT Compound Library | Inhibitor Library | NO PAINS Compound Library | Stem Cell Differentiation Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Transcription Factor-Targeted Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1860.00/100mg |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-08-21 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY